Beauty conglomerates make acquisitions constantly. Most of them barely move the needle. On March 31, 2026, L’Oréal and Kering announced the completion of a deal that is genuinely different in scale and implication — a €4 billion cash transaction that hands L’Oréal the House of Creed alongside 50-year exclusive licences for Bottega Veneta and Balenciaga fragrance and beauty products. The deal was first announced in October 2025. The regulatory process is now behind them. What happens next is what the industry has been watching for.
This surpasses L’Oréal’s 2023 purchase of Aesop for $2.5 billion, making it the largest acquisition in the company’s history. The price alone signals how seriously both sides view the opportunity. But the more interesting number is fifty, as in years. The licensing agreements attached to this deal are not short-term partnership arrangements. They are a generational commitment to building something that will outlast the people who signed the contracts.
What L’Oréal Actually Gets
Must Read: Kering and L’Oréal Finalize Acquisition, Fenty Beauty Partners with WhatsApp https://t.co/jwojHi7jzt
— Fashionista.com (@Fashionista_com) April 1, 2026
The headline asset is the House of Creed. Creed is one of the world’s foremost luxury fragrance houses, and its inclusion in the deal gives L’Oréal immediate credibility at the very top of the prestige fragrance market. This is not a brand that needs to be built. It is a brand that needs to be stewarded correctly, which is a different and arguably harder challenge.
Alongside Creed, L’Oréal secures 50-year, exclusive licences to create, develop, and distribute beauty and fragrance products underthe Balenciaga and Bottega Veneta brands. Both are among the most culturally potent fashion names operating today. Balenciaga’s presence in fragrance has been growing, and Bottega Veneta’s quiet luxury positioning translates naturally into beauty.
L’Oréal has also secured a 50-year exclusive licence for Gucci, which will take effect when Gucci’s existing agreement with Coty expires. That Gucci clause is worth noting separately — it is a long-range bet that the brand’s beauty potential has not yet been fully realised under its current arrangement.
The deal is structured as a cash payment, with L’Oréal paying royalties to Kering under the ongoing arrangement.
Why L’Oréal Wanted This
The acquisition fits a very clear strategic logic. L’Oréal Luxe already grew the Yves Saint Laurent beauty business from €649 million to €2 billion in revenue over two decades. That track record is the implicit argument for why Balenciaga, Bottega Veneta, and Gucci are better placed in L’Oréal’s hands than anywhere else. The company has proven it can take a fashion house’s beauty licence and turn it into a genuinely significant business over time.
L’Oréal Group CEO Nicolas Hieronimus framed the deal as a milestone for the company’s position at the top of both beauty and luxury beauty: “We will now work together, over the next fifty years, to write the next chapter of these iconic brands, to unlock their immense growth potential.” The fifty-year framing is not incidental. It signals that L’Oréal is not buying these licences to flip them or to mine short-term value. It is buying a permanent place at the intersection of fashion and fragrance.
Why Kering Was Willing to Sell
Kering reported a 13% decline in revenue for its full-year 2025 results. That context matters. The sale is a balance sheet decision at a moment when the company needed to stabilise. By monetising Kering Beauté, the group raises significant capital while simultaneously creating a structure in which its fashion houses’ beauty arms are managed by people who do nothing but think about beauty.
Kering CEO Luca de Meo described it as opening “a new phase of acceleration” for its brands, allowing them to fully realise their potential in fragrances and cosmetics while drawing on L’Oréal’s global infrastructure.
There is something honest in that framing. Running a global beauty operation at scale requires capabilities that a fashion conglomerate, even one the size of Kering, does not necessarily have in the same depth as a company whose entire existence is built around beauty.
The Wellness and Longevity Angle
There is a longer-term thread in this deal that deserves attention. Both companies confirmed they are exploring a joint venture focused on wellness and longevity. This is not a minor add-on. Wellness and longevity are among the fastest-growing areas in luxury consumer spending. Kering brings fashion credibility. L’Oréal brings scientific infrastructure. Together, they are well-positioned to enter this space.
The details remain limited for now. But two companies executing a $4.6 billion deal still chose to highlight this initiative. That suggests it is more than a symbolic note. Watch this space.
The luxury beauty landscape has been evolving for years. L’Oréal’s acquisition of Kering Beauté is not just another transaction. It signals where serious investment in beauty is heading and who is positioned to lead it. L’Oréal operates 22 research centres across seven regional hubs. Its Research and Innovation team includes more than 4,000 scientists. The company has the infrastructure to deliver on its promise. The next fifty years of Balenciaga, Bottega Veneta, and Gucci beauty now sit in L’Oréal’s hands.
Featured image: Jakub Porzycki/Getty Images
Woman Sues L’Oreal Claiming Hair Relaxer Caused Uterine Cancer
